Postpartum Depression
According to the Centers for Disease Control and Prevention, mental health conditions are the leading cause of maternal mortality1, with postpartum depression (PPD) among the most common complications during and after pregnancy.2 During pregnancy, levels of certain hormones rise and then rapidly fall after giving birth. These hormone shifts may put some women at risk for developing this serious disorder. In the U.S., it is estimated approximately 1 in 8 women experience symptoms of PPD3 and approximately half of all PPD cases may go undiagnosed without appropriate screening.4,5
Postpartum depression can have devastating consequences for a woman and for her family, which may include significant functional impairment, depressed mood and/or loss of interest in her newborn, and associated symptoms of depression such as loss of appetite, difficulty sleeping, worry or feeling overly anxious, motor challenges, lack of concentration, loss of energy and poor self-esteem.
ZURZUVAE® (zuranolone) CIV, in collaboration with Biogen, is the first and only oral, 14-day treatment now available for adults with postpartum depression.
ZULRESSO® (brexanolone) CIV, an in-patient 60-hour infusion, was FDA approved in 2019 as the first treatment for patients 15 years and older with postpartum depression.